I think you're wrong here. Even though RCs are zealously discussed here, I'm sure most of long-time members would agree with me that we don't really want a shitload of untested compounds flooding the market about which less and less is known about. I think the problem is a serious one, I've been recently seeing weirder and weirder compounds being tested. It gets problematic because, while for instance with most cathinones we had something to extrapolate from, structurally novel compounds have completely unknown toxicity. Many people don't realise it but it may suddenly turn out that one of these has extreme consequences and no matter how sorry you might be afterwards it just won't help. There's always a risk, sure, but there is no way you could assess it with new compounds structurally unrelated or hardly related to classes of compounds that we already know about.
Obviously new analogue acts have a lot to do with it, but let's not blame only one side. RC's business is about money like any other business, but it differs in that it may have a dramatic impact on people's health, so it should automatically come with great responsibility. Thus the quality and not the quantity should be definitely the deciding factor. The revenues for the people behind this are enormous, so perhaps such entrepreneurs should invest into more serious research if they want to introduce completely new classes of compounds, and not only treat people as if they were lab mice (it's always people's choice, sure, but I have some doubts whether they always make a fully conscious decision, I caught myself on taking too much risk without proper analysis first more than once). I'm sure we'd all like to have harmless alternatives, so why not get down to it as it should be done, with facts and not just subjective effects? There's still a great number of small molecules with potentially psychoactive effects, statistically they can't be all good and harmless.